logo
Twitter
Discord
Email
logo
ICON Public Limited Company

ICON Public Limited Company

NASDAQ•ICLR
CEO: Dr. Steven A. Cutler MBA, Ph.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1998-05-15
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Contact Information
South County Business Park, Leopardstown, Dublin, D18 X5R3, Ireland
353-1-291-2000
www.iconplc.com
Market Cap
$14.08B
P/E (TTM)
23.8
25.8
Dividend Yield
--
52W High
$228.29
52W Low
$125.10
52W Range
57%
Rank32Top 16.7%
5.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$2.04B+0.63%
4-Quarter Trend

EPS

$0.03-98.72%
4-Quarter Trend

FCF

$351.89M-2.07%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Income from Operations Surges Income from operations increased 14.8% to 1.10B USD; operating margin expanded significantly to 13.3% from 11.8% in 2023.
Revenue Growth Continues Globally Revenue increased 2.0% to 8.28B USD in 2024, driven by acquisitions and organic growth across US, Europe, and Rest of World.
Net Debt Significantly Reduced Total net debt decreased 9.3% to 3.43B USD from 3.78B USD, reflecting substantial mandatory and voluntary principal repayments.
Operating Cash Flow Strong Net cash provided by operating activities increased 10.8% to 1.29B USD, primarily due to favorable changes in working capital timing.

Risk Factors

UPO Conversion Rate Slows Unsatisfied Performance Obligation (UPO) reached 15.9B USD, but only 47% is expected to convert to revenue in the next 12 months.
Restructuring Charges Double Restructuring charges increased 103.0% to 92.1M USD in 2024, reflecting workforce reduction and office consolidation programs.
Variable Interest Rate Exposure Fluctuations in interest rates adversely affect results; 27% of outstanding debt remains subject to variable interest rates.
Cybersecurity and System Failures System failures, security breaches, or cyber attacks could materially limit operations and adversely affect financial results and reputation.

Outlook

Accelerating Clinical Research with AI Focus on AI Centre of Excellence to accelerate trials, optimize resources, and ensure compliance while upholding data privacy standards.
Expanding Patient-Centric Trials Continued investment in Accellacare network and decentralized trials to improve patient recruitment and retention globally.
Increased Share Buyback Capacity Board authorized additional buyback program up to 750.0M USD, allowing total repurchase capacity of 1.0B USD.
Commitment to Emissions Reduction SBTi validated near-term targets: 61.2% Scope 1/2 GHG reduction by FY2028 from FY2019 base year.

Peer Comparison

Revenue (TTM)

Fresenius Medical Care AGFMS
$21.68B
+2.1%
Universal Health Services, Inc.UHS
$16.99B
+10.2%
Smith & Nephew plcSNN
$11.61B
+9.9%

Gross Margin (Latest Quarter)

Royalty Pharma plcRPRX
100.0%
+0.0pp
Universal Health Services, Inc.UHS
90.8%
+0.6pp
Smith & Nephew plcSNN
70.6%
+0.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ILMN$20.61B29.930.0%41.7%
HOLX$16.76B29.811.7%27.8%
RPRX$16.72B16.315.2%43.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.0%
Moderate Growth
4Q Net Income CAGR
-79.2%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 18, 2026
|
EPS:$3.34
|
Revenue:-
Reports
All Years
  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 21, 2025|
    Revenue: $8.28B+2.0%
    |
    EPS: $9.60+28.7%
    Miss
  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 23, 2024|
    Revenue: $8.12B+4.9%
    |
    EPS: $7.46+20.3%
    Miss
  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Feb 24, 2023|
    Revenue: $7.74B+41.2%
    |
    EPS: $6.20+171.9%
    Miss
  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 1, 2022|
    Revenue: $5.48B+95.9%
    |
    EPS: $2.28-63.8%
    Miss
  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Feb 24, 2021|
    Revenue: $2.80B-0.3%
    |
    EPS: $6.29-8.2%
    Meet